SillaJen IPO Part 5 -Â Revenue & Valuation Estimates with Pexa-Vec's First Commercialization Year
We need to examine the size of SillaJen's expected sales in 2020, which is the reference year for its entire valuation. With an assumption that...
442 Views
SillaJen IPO Part 4 - IPO Price & Post-IPO Risks
SillaJen IPO price was set at ₩15,000, the lowest end of the indicative price band, after conducting the demand survey from (Nov 23-24) the...
372 Views
Cadila Healthcare: Potential More than 30% Upside.
Cadila Healthcare Ltd (CDH IN) is the 4th largest pharmaceutical company in India and 9th largest generic drug company in the U.S. At FY 2018 P/E...
255 Views
MedTech as an Investment Theme
Medicine is changing. For hundreds of years, the key drivers of progress were biology and chemistry. Now they are data science and software.Big...
394 Views
Andrew on Tech: IOT Everywhere
The proliferation of IoT: With over 25% 5-year CAGR for IoT devices shipment and wafer foundry market but a very fragmented vendors list, we...
437 Views